Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion
Authors:
- Takaya ShimuraTakaya Shimura
- Michihiro YoshidaMYMichihiro Yoshida
- Shinji FukudaSFShinji Fukuda
- Masahide EbiMEMasahide Ebi
- Yoshikazu HirataYHYoshikazu Hirata
- Tsutomu MizoshitaTMTsutomu Mizoshita
- Satoshi TanidaSTSatoshi Tanida
- Hiromi KataokaHKHiromi Kataoka
- Takeshi KamiyaTKTakeshi Kamiya
- Shigeki HigashiyamaSHShigeki Higashiyama
- Takashi JohTJTakashi Joh
Open Access
- 30 May 2012
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 205
Abstract
Membrane-anchored heparin-binding epidermal growth factor-like growth factor (proHB-EGF) yields soluble HB-EGF, which is an epidermal growth factor receptor (EGFR) ligand, and a carboxy-terminal fragment of HB-EGF (HB-EGF-CTF) after ectodomain shedding. We previously reported that HB-EGF-CTF and unshed proHB-EGF which has the cytoplasmic domain of proHB-EGF (HB-EGF-C), translocate from the plasma membrane to the nucleus and regulate cell cycle after shedding stimuli. However, the significance of nuclear exported HB-EGF-C in human gastric cancer is unclear. We investigated the relationship between intracellular localization of HB-EGF-C and clinical outcome in 96 gastric cancer patients treated with gastrectomy. Moreover, we established stable gastric cancer cell lines overexpressing wild-type HB-EGF (wt-HB-EGF) and mutated HB-EGF (HB-EGF-mC), which prevented HB-EGF-C nuclear translocation after shedding. Cell motility between these 2 gastric cancer cell lines was investigated using a transwell invasion assay and a wound healing assay. Of the 96 gastric cancer cases, HB-EGF-C immunoreactivity was detected in both the nucleus and cytoplasm in 19 cases (19.8 %) and in the cytoplasm only in 25 cases (26.0 %). The nuclear immunoreactivity of HB-EGF-C was significantly increased in stage pT3/4 tumors compared with pT1/2 tumors (T1/2 vs. T3/4: 11.1 % vs. 36.4 %, P < 0.01). The growth of wt-HB-EGF- and HB-EGF-mC-expressing cells significantly increased compared with control cells, but the growth of HB-EGF-mC-expressing cells was significantly decreased compared with wt-HB-EGF-expressing cells. Gastric cancer cell invasion obviously increased in wt-HB-EGF-expressing cells, but invasion in HB-EGF-mC-expressing cells showed a slight increase compared with control cells. Moreover, wt-HB-EGF overexpression increased the effectiveness of wound healing, but had no significant effect in HB-EGF-mC-expressing cells. Both the function of HB-EGF as an EGFR ligand and a novel signal for HB-EGF-C nuclear translocation induce gastric cancer growth, whereas HB-EGF-C nuclear translocation independently plays a critical role in gastric cancer invasion. The present study demonstrated that HB-EGF-C nuclear translocation might be crucial in gastric cancer invasion. HB-EGF-C nuclear translocation may offer a prognostic marker and a new molecular target for gastric cancer therapy.Keywords
This publication has 28 references indexed in Scilit:
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancersBritish Journal of Cancer, 2009
- Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membraneJournal of Cell Biology, 2008
- Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligandsCancer Science, 2008
- An intermediary role of proHB‐EGF shedding in growth factor‐induced c‐Myc gene expressionJournal of Cellular Physiology, 2007
- Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcomeCancer, 2007
- Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistanceOncogene, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancerBritish Journal of Cancer, 2005
- Significance of the association between heparin‐binding epidermal growth factor‐like growth factor and CD9 in human gastric cancerInternational Journal of Cancer, 2002